CANOPY GROWTH CORPORATION + SUPREME CANNABIS

Canopy Growth's Acquisition of Supreme Cannabis (TSX: FIRE)

April 2021



DISCLAIMERS AND CAUTIONARY STATEMENTS

This presentation contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Canopy Growth Corporation ("Canopy" or "Canopy Growth"), The Supreme Cannabis Company, Inc. ("Supreme" or "Supreme Cannabis") or their respective subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this presentation. Examples of such statements include statements with respect to the timing and outcome of the Arrangement (as defined below), the anticipated benefits of the Transaction, the estimated potential synergies as a result of the Transaction, the anticipated timing of the Supreme Cannabis special meeting of shareholders and the closing of the Transaction (as defined below), the satisfaction or waiver of the closing conditions set out in the arrangement agreement between Canopy and Supreme announced on April 8, 2021, including receipt of all regulatory approvals. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including assumptions as to the time required to prepare and mail meeting materials to Supreme Cannabis shareholders; the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholder approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Transaction; the prompt and effective integration of Canopy's and Supreme's businesses and the ability to achieve the anticipated synergies contemplated by the Transaction; inherent uncertainty associated with financial or other projections; risks related to the value of the Canopy common shares to be issued pursuant to the Transaction; the diversion of management time on Transaction-related issues; expectations regarding future investment, growth and expansion of Canopy's and Supreme's operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; risks related to infectious diseases, including the impacts of the Covid-19 pandemic; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis, political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of Canopy filed with Canadian securities regulators and available under Canopy's profile on SEDAR at www.sedar.com and with the United States Securities and Exchange Commission through EDGAR at www.sec.gov/edgar, including Canopy's annual report on Form 10-K for the year ended March 31, 2020, as amended, and in the public filings of Supreme Cannabis filed with Canadian securities regulators and available under Supreme Cannabis' profile on SEDAR at www.sedar.com, including Supreme Cannabis' annual information form for the year ended June 30, 2020.

In respect of the forward-looking statements and information concerning the anticipated benefits and completion of the Transaction and the anticipated timing for completion of the Transaction, Canopy and Supreme Cannabis have provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although Canopy and Supreme Cannabis believe that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this presentation are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, estimated or expected. Although Canopy and Supreme Cannabis have attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this presentation are made as of the date of this presentation and Canopy and Supreme Cannabis do not undertake any obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.





TRANSACTION RATIONALE



Benefits for Supreme Shareholders: Attractive Premium, Enhanced Liquidity and Continued Participation





Benefits for Canopy Shareholders: Strengthened Brand Portfolio and Production Capabilities; Attractive Financial Synergies



Cost Synergies and Potential to Accelerate Revenue Growth







Solidifies Canopy's Leadership Position in the Canadian Recreational Market



Top-tier, Branded Consumer-Focused Platform



Well-Capitalized for Continued Global Growth





TRANSACTION SUMMARY

Proposed Transaction

- Canopy Growth to acquire all of the issued and outstanding shares of Supreme Cannabis (the "Transaction") by way of a court approved Plan of Arrangement (the "Arrangement")
- Supreme Cannabis shareholders will receive 0.01165872x of a Canopy common share and \$0.0001 in cash in exchange for each Supreme cannabis share held
- Based on Canopy's closing share price on the TSX of \$37.74 on April 7, 2021, the transaction implies a value of \$0.44 per Supreme share
- Implied premium of ~66% to Supreme's closing price on April 7, 2021

Key
Approvals &
Conditions

- Already obtained approval of both Board of Directors
- Supreme shareholder approval required
- Two fairness opinions provided
- Regulatory and court approvals required, as well as other customary closing conditions

Deal Protection

- Termination fee payable to Canopy in the amount of \$12.5 mm if the transaction is terminated under certain circumstances
- Supreme is subject to customary non-solicitation provisions with fiduciary out and right to match

Timing

- Special meeting of Supreme shareholders is expected to occur in June 2021
- Expected closing by the end of June 2021



COMBINED TRANSACTION HIGHLIGHTS

✓ Solidifies Canopy's Leadership Position in the Canadian Recreational Market

- The transaction combines Canopy's preeminent position with Supreme Cannabis' Top-10 position in Canada to create a pro forma Canadian recreational market share of 13.6%⁽¹⁾, including 7ACRES holding Canada's number one premium flower brand position, number one in PAX vapes, and Top-5 in pre-rolled joints⁽¹⁾
- Combined pro-forma market share estimated to be 23.3% and 21.4% in the premium segment in Ontario and British Columbia, respectively⁽²⁾

✓ Adds Premium Brands to Canopy's Portfolio

- The addition of Supreme Cannabis' premium brands, 7ACRES and 7ACRES Craft Collective, complement Canopy's current consumer offering and will strengthen Canopy's brand assortment, with both brands expected to continue to grow with further investment and expansion
- Possess four of the top ten Canadian cannabis brands based on brand awareness⁽³⁾
- Supreme Cannabis' Blissco and Truverra brands also add breadth to Canopy's market presence in both the recreational and medical markets
- Potential to further leverage Canopy's consumer insights, R&D and innovation capabilities to accelerate new product launches

✓ Brings a Premium, Low-Cost and Scalable Cultivation Facility to Canopy's Production Capabilities

- Indoor/greenhouse cultivation platform with demonstrated capability of consistently producing premium flower from sought-after strains at low-cost with significant potential for scaling
- Strengthens genetic library and adds expertise in cultivation, strain development and extraction

✓ Opportunity to Achieve Cost Synergies Estimated at Approximately \$30 mm Within Two Years

Anticipated post-transaction cost synergy opportunities across both cost of goods sold and sales, general and administrative expenses, as Canopy optimizes and integrates
 Supreme's operations and shared services

✓ Well-Capitalized for Continued Global Growth

• Post-acquisition, Canopy's industry-leading balance sheet and cash position of ~\$2.5 bn⁽⁴⁾ positions the company for further expansion and product development





- 1. Market share data represents 01-Oct-20 through latest available data: Provincial Board data for ON online, PEI, NS (27/28-Mar-21) and NB (17-Mar-21); and Headset data for ON retail (28-Feb-21) and AB, BC and SK (31-Mar-21).
- Source: Canopy internal proprietary market share tool that utilizes point of sales data supplied by third-party data providers, government agencies and Canopy's own retail store operations across the country. Tool captures point of sale data from an average of 39% of stores in AB, BC, SK, MB and NFLD & Labrador, point of sale data from 100% of stores in NB, NS and PEI, as well as depletions and ecommerce sales data from the OCS for Q3 FY21.
- 3. Source: Brightfield Group Canada Brand Health Survey, W4 2020; aided brand awareness.
- 4. Pro-forma for debt financing announced on 18-Mar-21.

BENEFITS FOR SUPREME SHAREHOLDERS

✓ Secures an Immediate Attractive Premium for Supreme Cannabis Shareholders

• The transaction provides Supreme Cannabis shareholders with a premium per Supreme Cannabis share of approximately 66% based on the closing prices of the Supreme and Canopy common shares on the TSX on April 7, 2021

✓ Enhanced Trading Liquidity and Capital Markets Profile

Canopy common shares are highly liquid with an average daily trading volume of ~9.7 mm shares, representing ~C\$375 mm on a daily basis over the last 6 months through trading via both Nasdaq and TSX listings

✓ Participation by Supreme Cannabis Shareholders in the Future of Canopy

- Brand growth is anticipated with distribution supported by Canopy's robust sales and distribution network as well as superior consumer insights and R&D capabilities
- Supreme Cannabis shareholders will also benefit from Canopy's US CBD business and conditional positioning for continued exposure to the US market expansion
- Benefit from being a part of diversified cannabis company with established medical and international presence and key strategic partnership with Constellation Brands
- Transaction provides substantial financial scale and industry leading operational know-how to accelerate Supreme's growth strategy, future product development and innovation





BENEFITS TO BOTH CANOPY AND SUPREME SHAREHOLDERS

Supreme.


- Leading premium brands in Canada
- A premium, low-cost and scalable cultivation facility in Kincardine, ON













R&D focused on Plant Sciences, Human Effects and User Technology and Design

CANOPY GROWTH

 Advanced manufacturing operations in Smith Falls, ON













TRANSACTION DELIVERS SUBSTANTIAL FINANCIAL BENEFITS


- ✓ Opportunity to Achieve Potential Cost Synergies Estimated at Approximately \$30 mm Within Two-Years
 - Increase scale to drive improved utilization and fixed cost absorption
 - Production and supply chain optimization
 - SG&A savings from corporate overhead reduction and elimination of other duplicative expenses
 - These cost synergies are incremental to Canopy's announced \$150-\$200 mm cost savings program already underway
- ✓ Potential Revenue Upside
 - Combined capabilities and infrastructure expected to drive faster product commercialization and speed to market
 - Leverage Canopy's retail store network to increase penetration of Supreme products
- ✓ Ample Capital to Support Continued Growth
 - ~\$2.5 bn⁽¹⁾ in cash on balance sheet of pro-forma entity





BOLSTERS LEADERSHIP POSITION IN CANADIAN RECREATIONAL MARKET

LQ Recreational Net Revenue(1)








- L. LQ: Last Quarter. Show in C\$ mm. Select cannabis peers.
- Aphria discloses recreational revenue of \$72.1 mm on a gross basis, converted to net basis of \$56.3 mm using assumed excise tax rate of ~22% (Aphria's total last quarter effective cannabis excise tax for all cannabis revenues); Tilray based on last quarter recreational net revenue figure of US\$25.4 mm converted to CAD at 1.27x for a total of \$32.3 mm.
- 3. Includes ~C\$13 mm of recreational net revenue from Supreme and ~C\$67 mm in recreational net revenue from Canopy, pro-forma acquisition of Ace Valley.
- Includes ~C\$27 mm in recreational net revenue from HEXO and ~C\$13 mm in recreational net revenue from Zenabis.

LEADING MARKET SHARE POSITION IN CANADIAN RECREATIONAL MARKET⁽¹⁾







Source: Provincial Boards; Headset

Note: This market share data differs from Canopy's internal market share data provided during Canopy's previous earnings calls due to different methodologies and time periods

- Market share data represents 01-Oct-20 through latest available data: Provincial Board data for ON online, PEI, NS (27/28-Mar-21) and NB (17-Mar-21); and Headset data for ON retail (28-Feb-21) and AB, BC and SK (31-Mar-21)
- Pro-forma merger with Aphria.
- Pro-forma acquisition of Supreme.Pro-forma acquisition of Zenabis.

COMPLEMENTARY BRAND PORTFOLIO ADDRESSING FULL SPECTRUM OF CONSUMER SEGMENTS

Flower & Pre-rolls Vapes Beverages **Edibles Edible Extracts** Concentrates Medical 7 A C R E S Ultra **Premium** 7 A C R E S **®DOJA** QUATREAU (1) **Premium MACHINITY** blissco TOKYO SMOKE TOKYO SMOKE TOKYO SMOKE **MACHINITIES** HOUSEPLANT blissco blissco Spectrum Therapeutics¹ **Mainstream** 7 sugar sugar sugar sugar truverra leaf leaf leaf leaf **Value** Twd. Twd. Twd.





^{2.} Hiway brand concentrates include hash.

CANOPY GROWTH OVERVIEW

Financial Highlights

- o LQA⁽¹⁾ Revenue: ~\$610 mm
- Expect to achieve positive Adjusted EBITDA⁽²⁾ during the second half of FY 2022
- Strong Pro-forma balance sheet with cash & short-term investments of ~\$2.5 bn⁽³⁾

Leading Cannabis Business Focused on Canada, US and Germany

- Top-2 market share position in Canadian recreational market
- Leading market share in German medical market
- Scaling US business via CBD brands and CPG brands

Consumer-driven Approach; Focused on Execution and Increased Agility

- Building a differentiated product portfolio driven by consumer insights, R&D and innovation
- Entire organization oriented around aligning product innovation, market fit and sales execution

Strategic Relationship with Constellation Brands

- C\$5.8 bn of investment and a 38% ownership interest
- Ability to leverage strategic support through partnership





- 1. LQA: Last Quarter Annualized
 - As used by Canopy, Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted EBITDA is calculated as the reported net loss, adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; expected credit losses on financial assets and related charges; restructuring costs recorded in cost of goods sold; and charges related to the flow-through of inventory stepup on business combinations, and further adjusted to remove acquisition-related costs.
- Pro-forma for debt financing announced on 18-Mar-21.

CANOPY OFFERS ROBUST PRODUCTS ACROSS DISTINCT BRANDS

Flower and Pre-Rolls





- Highly curated and broad appeal
- Focused on terpenes and aromas





TOKYO SMOKE

- Appeals to enthusiasts
- Experience-based products



Twd.

Value brand





- High-quality flower grown in the Okanagan Valley and produced in small batches
- Expertly cultivated and hand-crafted

Vapes





- Exports medically approved vaporizers to 50 markets globally, with heat-not-burn technology to produce vapors instead of smoke
- Growing distribution network to expand U.S. consumer reach



Tokyo Smoke Luma: UL 8139 certified vape system with rechargeable batteries



510 Rechargeable **Battery Vape Pen** with buttonless activation: UL 8139 certified 510 cartridges

Edibles and Animal Health






SURITYPRO







- Recently launched Twd. gummies
- Martha Stewart CBD gummies, softgels and oil drops in the U.S.
- Pet CBD product portfolio under *Martha Stewart* branded Soft Baked Chews and Oil Drops and SurityPro (science-backed, vet endorsed) Soft Chews and Oil Drops





Beverages



Sport nutrition CBD beverages and gum through BioSteel currently sold in the U.S. market with additional products anticipated over time

Topicals





- This Works is a natural wellness skincare line with international presence
- This Works has CBD Boosters launched online in the U.S. & the U.K.
- First & Free offers hemp-derived CBD product line offered in a variety of formats, including softgels, oil drops and creams in the U.S.





CANOPY'S US ECOSYTEM STRATEGY

Invest in Scalable Brands

- Bring our THC brands into the US market through Multi-State Operator ("MSO") licensing or hemp-derived CBD extensions
- Create new CBD brands to meet consumer needs and desires
- Lead route-to-market and portfolio development with CPG brands

US MSO Relationships

- Positioned for an accelerated entry into US THC through existing relationships with Acreage & TerrAscend
- Path to deploy Canopy's IP into the US to build brand awareness and association



Constellation Brands

- Investment grade balance sheet strength and access to banking
- Leverage Constellation's powerful distributor network and key account relationships
- Sharing of best practices across Insights, R&D, and Operations
- Government Relations and Legal teams joint engagement with officials

Retail Banners

- Tokyo Smoke and Tweed retail store banners to build brand awareness
- Innovation testing ground
- Collection of sales data to drive Insights & Innovation





SUPREME CANNABIS OVERVIEW

Financial Highlights

- LQA⁽¹⁾ Revenue: ~\$75 mm
- \$3.6 mm positive Adj. EBITDA⁽²⁾ in most recent quarter (Q2 FY21 ended 31-Dec-2020)

Consumer-driven Brands and Products with Leading Presence

- o Top-10 LP in Canada with a ~3% market share (3)
- 7ACRES is the #1 premium flower and Top-5 pre-roll brand in Canada⁽⁴⁾
- #1 PAX Vape in Canada⁽⁴⁾

Supreme Facilities

Two centers of excellence, one for cultivation & processing (Kincardine) and one for extraction (Langley)

Broad Domestic & International Distribution

Products are offered across Canada and international medical sales in Israel and Australia





[.] LOA: Last Quarter Annualized.

As used by Supreme, Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted EBITDA is calculated as the reported net loss, adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; expected credit losses on financial assets and related charges; restructuring costs recorded in cost of goods sold; and charges related to the flow-through of inventory stepup on business combinations, and further adjusted to remove acquisition-related costs.

For an explanation and reconciliation of Adjusted EBITDA to related comparable financial information presented in the Financial Statements prepared in accordance with IFRS, refer to Supreme's management's discussion and analysis of financial results for the three and six months ended December 31, 2020 filed on SEDAR.

Market share data represents 01-Oct-20 through latest available data: Provincial Board data for ON online, PEI, NS (27/28-Mar-21) and NB (17-Mar-21); and Headset data for ON retail (28-Feb-21) and AB, BC and SK (31-Mar-21).

Source: Canopy internal proprietary market share tool that utilizes point of sales data supplied by third-party data providers, government agencies and Canopy's own retail store operations across the country. Tool captures point of sale data from an average of 39% of stores in AB, BC, SK, MB and NFLD & Labrador, point of sale data from 100% of stores in NB. NS and PEI. as well as depletions and ecommerce sales data from the OCS for 0.3 FY21.

DIVERSE CANNABIS BRANDS AND PRODUCTS

High-Quality Products at Every Key Price Point



7 A C R E S
CRAFT
COLLECTIVE



sugar leaf



Multi-award-winning cannabis brand regarded for its premium flower products and inputs.

For discerning recreational consumers.

Whole Flower

Whole Flower Pre-Rolls

Vaporizer (PAX Pods)

Concentrates

Ultra premium brand extension delivering high-potency craft cannabis products.

For experienced enthusiast consumers.

Whole Flower

Pre-Rolls

Affordable cannabis brand delivering quality products at an accessible price.

For experienced value-oriented consumers.

Pre-Rolls

Vaporizer

Hash

Concentrates

Accessible recreational brand focusing on high-quality convenience products.

For new cannabis and convenience consumers.

Pre-Rolls

THC and CBD Oils

Gummies

Vaporizer (5:10)

Premium wellness brand producing high-quality cannabis and CBD offerings.

For wellness-focused consumers.

CBD Oils

Whole Flower

Pre-Rolls

Vaporizer

International medical brand delivering CBD and cannabis products.

For medical cannabis consumers.

CBD Medicinal Products

Medical Cannabis



KINCARDINE: SUPREME'S CULTIVATION CENTER OF EXCELLENCE

7ACRES FACILITY | KINCARDINE, ONTARIO

Core Capabilities

Hybrid facility | Indoor sealed cultivation with greenhouse roof

Product | Produces premium flower with high consistency in small batch grows

Advanced processing | Proprietary whole-plant dry and hand-trim finish including small batch processing for craft production

Value-add processing | Pre-roll and concentrates production

Automated packaging | Packaged to high-quality visual specification

Genetics practice | Cambium Plant Sciences R&D lab within 7ACRES

Scalability | Premium and scalable cultivation facility with demonstrated record of producing premium flower at a low cost









Canopy Growth Corporation

NASDAQ: CGC | TSX : WEED

Canopygrowth.com

The Supreme Cannabis Company

TSX: FIRE

Supreme.ca

THANK YOU

Investor Relations:

Judy Hong
Vice President, Investor Relations
Judy.Hong@canopygrowth.com

Tyler Burns
Director, Investor Relations
Tyler.Burns@canopygrowth.com

Craig MacPhail Investor Relations ir@supreme.ca



